<![CDATA[Acquired Immune Deficiency Syndrome (AIDS) is the cause of death of million people in the world in 2016. The prevalence of Human Immunodeficiency Virus-1 (HIV-1) infection in Indonesia is still high and number of death caused by HIV-1-related diseases shows an apprehensive number. Treatment of HIV/AIDS nowadays is not effective to eradicate HIV-1 and also cause adverse effects. Previous research found RN-18 as a specific antagonistic molecule for viral infectivity factor (Vif) that can trigger Vif degradation and maintain intracellular A3G level. The aim of this review is to examine the potential of NARN-18 based PLGA-CS-PEG nanoparticles through oral administration in the management of HIV-1 infection. Method of this article is using literature review method. Literature searching is done by using “A3G”, “HIV-1”, “PLGA-CS-PEG”, “RN-18”, and “Vif” as keywords in search engine. 13a molecule, that is the analogue of RN-18, is used in the modality because it has better effectiveness and solubility compared with RN-18. By using PLGA, PEG, and chitosan (CS) as nanoparticles that carries RN-18 analogue makes the modality can be taken orally and targets T cell as soon as it enters the blood stream. It also can increase the efficiency of drug release and drug loading of the modality. NARN-18 constructed by using PLGA-PEG-CS nanoparticle makes the modality can be administered orally, increase its half-life in the body, and also increase the inhibition effect of RN-18 analogue. Therefore, this combination is one of the potential therapy in HIV-1 infection treatment.]]>
Copyrights © 2020
